Covidien has announced that the company plans to spin off its pharmaceutical unit into a public company to increase shareholder value.  Covidien released a statement saying that the spin off would give the new company the financial and strategic flexibility to pursue its growth plans and allow it to bring new products to market.  The pharmaceutical unit generates about $2 billion in annual revenue. Covidien...